News: vemurafenib

Colon Cancer Added to Gene Mutation Testing

Thursday, July 19th, 2012

Vanderbilt-Ingram Cancer Center has initiated tumor mutation testing for a limited number of patients with metastatic colorectal cancer. This pilot project for colorectal cancer is part of VICC’s Personalized Cancer Medicine Initiative (PCMI), a program to identify genetic mutations in a patient’s tumor that may be useful in matching the appropriate therapy with each patient. […]

Melanoma Drug Risks Studied

Friday, March 23rd, 2012

Melanoma patients who are treated with new oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. A new study co-authored by Vanderbilt-Ingram Cancer Center investigators and researchers from 12 other cancer centers discovered clues that may explain what is triggering these secondary cancers. VICC’s Igor Puzanov, M.D., assistant professor […]

Melanoma Drug Nearly Doubles Survival

Friday, February 24th, 2012

Investigators from Vanderbilt-Ingram Cancer Center and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. More than half of patients who were treated with the novel drug vemurafenib, known commercially as Zelboraf, responded to treatment and experienced an impressive […]

Investigators Seek Clues to Resistance to Melanoma Drug

Friday, January 27th, 2012

Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug. Approximately half of all patients with the most deadly form of skin cancer have a mutation in the BRAF gene in their tumors that drives the […]